Authors:
GORE SD
ROWINSKY EK
MILLER CB
GRIFFIN C
CHEN TL
BOROWITZ M
DONEHOWER RC
BURKS KL
ARMSTRONG DK
BURKE PJ
GREVER MR
KAUFMANN SH
Citation: Sd. Gore et al., A PHASE-II WINDOW STUDY OF TOPOTECAN IN UNTREATED PATIENTS WITH HIGH-RISK ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA, Clinical cancer research, 4(11), 1998, pp. 2677-2689
Citation: Sd. Gore et al., IMPACT OF EXOGENOUS GROWTH-FACTORS ON PROLIFERATION AND CHEMOSENSITIVITY OF MINIMAL RESIDUAL ACUTE MYELOID-LEUKEMIA, Leukemia & lymphoma, 29(3-4), 1998, pp. 339-350
Authors:
SMITH BD
BAMBACH BJ
VALA MS
BARBER JP
ENGER C
BRODSKY RA
BURKE PJ
GORE SD
JONES RJ
Citation: Bd. Smith et al., INHIBITED APOPTOSIS AND DRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA, British Journal of Haematology, 102(4), 1998, pp. 1042-1049
Citation: Sd. Gore et al., IMPACT OF THE PUTATIVE DIFFERENTIATING AGENTS SODIUM PHENYLBUTYRATE AND SODIUM PHENYLACETATE ON PROLIFERATION, DIFFERENTIATION, AND APOPTOSIS OF PRIMARY NEOPLASTIC MYELOID CELLS, Clinical cancer research, 3(10), 1997, pp. 1755-1762
Citation: Sh. Kaufmann et al., ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY (VOL 23, PG 71, PG 1996), Leukemia & lymphoma, 24(5-6), 1997, pp. 3-3
Citation: Lj. Weng et al., SYNERGY BETWEEN RETINOIC ACID (IU) AND THE PUTATIVE DIFFERENTIATING AGENT SODIUM PHENYLBUTYRATE (SPB) PROMOTES MAXIMAL CYTOSTASIS AND DIFFERENTIATION OF MYELOID CELLS AT CLINICALLY ACHIEVABLE DOSES OF SPB, Blood, 90(10), 1997, pp. 1469-1469
Authors:
SOTOMAYOR EM
PIANTADOSI S
MILLER CB
KARP JE
KAUFMANN SH
BRAINE H
HUMPHREY RL
BURKE PJ
GORE SD
Citation: Em. Sotomayor et al., LONG-TERM FOLLOW-UP OF INTENSIVE, ARA-C-BASED CHEMOTHERAPY FOLLOWED BY BONE-MARROW TRANSPLANTATION (BMT) FOR ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - IMPROVED SURVIVAL WITH ALLOGENEIC, BUT NOT AUTOLOGOUS BMT, Blood, 90(10), 1997, pp. 1484-1484
Authors:
KAUFMANN SH
SVINGEN PA
GORE SD
ARMSTRONG DK
CHENG YC
ROWINSKY EK
Citation: Sh. Kaufmann et al., ALTERED FORMATION OF TOPOTECAN-STABILIZED TOPOISOMERASE-I DNA-ADDUCTSIN HUMAN LEUKEMIA-CELLS, Blood, 89(6), 1997, pp. 2098-2104
Citation: Sd. Gore et al., IDENTIFICATION OF THE LARGEST INDIVIDUAL-SAMPLE VALUE USING COMPOSITESAMPLE DATA AND CERTAIN MODIFICATIONS OF THE SWEEP-OUT METHOD, Environmental and ecological statistics, 3(3), 1996, pp. 219-234
Citation: Mt. Boswell et al., ANNOTATED-BIBLIOGRAPHY OF COMPOSITE SAMPLING PART-A - 1936-92, Environmental and ecological statistics, 3(1), 1996, pp. 1-50
Authors:
ROWINSKY EK
KAUFMANN SH
BAKER SD
MILLER CB
SARTORIUS SE
BOWLING MK
CHEN TL
DONEHOWER RC
GORE SD
Citation: Ek. Rowinsky et al., A PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN INFUSED OVER 30 MINUTES FOR 5 DAYS IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA, Clinical cancer research, 2(12), 1996, pp. 1921-1930
Citation: Sh. Kaufmann et al., ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY, Leukemia & lymphoma, 23(1-2), 1996, pp. 71-83
Authors:
GORE SD
MILLER CB
WENG LJ
BURKS K
GRIFFIN CA
CHEN TL
BURKE PJ
GREVER M
ROWINSKY EK
Citation: Sd. Gore et al., IMPROVED HEMATOPOIESIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML) FOLLOWING ADMINISTRATION OF THE PUTATIVE DIFFERENTIATING AGENT SODIUM PHENYLBURYRATE (SPB), Blood, 88(10), 1996, pp. 2315-2315
Authors:
GORE SD
WENG LJ
JONES RJ
COWAN K
ZILCHA M
PIANTADOSI S
BURKE PJ
Citation: Sd. Gore et al., IMPACT OF IN-VIVO ADMINISTRATION OF INTERLEUKIN-3 ON PROLIFERATION, DIFFERENTIATION, AND CHEMOSENSITIVITY OF ACUTE MYELOID-LEUKEMIA, Clinical cancer research, 1(3), 1995, pp. 295-303
Citation: Sd. Gore et al., STEEL FACTOR SUPPORTS THE CYCLING OF ISOLATED HUMAN CD34(-FACTORS() CELLS IN THE ABSENCE OF OTHER GROWTH), Experimental hematology, 23(5), 1995, pp. 413-421
Citation: Sd. Gore et Pj. Burke, LONG-TERM SURVIVAL OF SUBSETS OF PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH INTENSIVE CHEMOTHERAPY, Blood, 86(10), 1995, pp. 1342-1342
Authors:
BURKE PJ
ZAHURAK M
GORE SD
ADJEI A
STRYZAK J
Citation: Pj. Burke et al., THE PROGNOSTIC FACTOR SCORE MODEL AND A SEQUENTIAL LIKELIHOOD RATIO TEST RAPIDLY DETERMINE THE VALUE OF TRANSLATIONAL INTERVENTION IN PATIENTS WITH MINIMAL RESIDUAL AML, Blood, 86(10), 1995, pp. 2995-2995
Authors:
GORE SD
DONNENBERG AD
ZEHNBAUER BA
WENG LJ
BURKE PJ
Citation: Sd. Gore et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (CM-CSF), GIVEN CONCURRENTLY WITH INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML), AUGMENTS THE SYNDROME OF T-LYMPHOCYTE RECOVERY, Leukemia, 8(3), 1994, pp. 409-419
Citation: Sd. Gore et al., IDENTIFICATION OF GROWTH FACTOR-RESPONSIVE ACUTE MYELOGENOUS LEUKEMIABASED ON FACTOR-DEPENDENCE FOR SURVIVAL AND PROLIFERATION, Leukemia, 8(11), 1994, pp. 1854-1863
Authors:
ROWINSKY EK
ADJEI A
DONEHOWER RC
GORE SD
JONES RJ
BURKE PJ
CHENG YC
GROCHOW LB
KAUFMANN SH
Citation: Ek. Rowinsky et al., PHASE-I AND PHARMACODYNAMIC STUDY OF THE TOPOISOMERASE I-INHIBITOR TOPOTECAN IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA, Journal of clinical oncology, 12(10), 1994, pp. 2193-2203
Citation: Lj. Weng et al., WILL GROWTH-FACTOR AUGMENTATION DURING POSTREMISSION THERAPY FOR AML OVERCOME DRUG-RESISTANCE, Experimental hematology, 22(8), 1994, pp. 772-772